Ispire Technology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.33next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Fiscal Q1 2027 Quarterly Report (Form 10-Q) | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly18.7MTarget: Sequential growth and recovery toward historical levels above $25M
Gross Margin Quarterly1,070.0%Target: Fatter margins through ODM technology and proprietary design
Diluted EPS (TTM) Quarterly-0.6Target: Breakeven and positive EPS
Watch Items
- FDA PMTA Approval for Age-Gating TechnologyTrigger: Official FDA decision or regulatory milestone recognitionAction: Re-evaluate the long-term growth rate and target valuation multiples upward upon approval.
- Cash Burn and Operating Cash FlowTrigger: Operating Cash Flow falling below -$5 million annuallyAction: Assess liquidity risk, potential dilution from capital raises, or debt restructuring needs.
Research as of 19 Jun 2026